Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 44: 420-427, 1998;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (15)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lieberman, R.
Right arrow Articles by Kelloff, G. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lieberman, R.
Right arrow Articles by Kelloff, G. J.
Related Collections
Right arrow Therapeutic Drug Monitoring Conference
Right arrow Evidence Based Laboratory Medicine and Test Utilization
Right arrow Drug Monitoring and Toxicology
(Clinical Chemistry. 1998;44:420-427.)
© 1998 American Association for Clinical Chemistry, Inc.

TDM Conference

Development of new cancer chemoprevention agents: role of pharmacokinetic/pharmacodynamic and intermediate endpoint biomarker monitoring

Ronald Liebermana, James A. Crowell, Ernest T. Hawk, Charles W. Boone, Caroline C. Sigman, and Gary J. Kelloff

a Author for correspondence. Fax 301-402-0553; e-mail Liebermr{at}dcpcepn.nci.nih.gov.


Abstract

Recently, several promising strategies have been advanced for improving the efficiency of new agent development. These include pharmacokinetic/pharmacodynamic (PK/PD) and intermediate endpoint bio-marker (IEB) monitoring. Here, we review their essential role as practical tools for guiding the evaluation of agents for cancer chemoprevention (CP) and provide examples of CP agents that utilize these approaches. Several important categories of IEBs are delineated, including histologically based (intraepithelial neoplasias and nuclear morphometry). The use of select IEBs combined with a Bayesian method for clinical trial monitoring for rapid identification of ineffective or promising agents is discussed. The similarities between IEB and TDM are described. Finally, we present future tools for enhanced monitoring of CP agents that will impact on laboratory medicine and are also applicable to many other drug classes, e.g., laser capture microdissection and cDNA chip microarrays that assess gene expression patterns of precancerous and cancerous lesions.




The following articles in journals at HighWire Press have cited this article:


Home page
 J. Clin. Pathol.Home page
F. Fend and M. Raffeld
Laser capture microdissection in pathology
J. Clin. Pathol., September 1, 2000; 53(9): 666 - 672.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
K. Singletary
Diet, Natural Products and Cancer Chemoprevention
J. Nutr., February 1, 2000; 130(2): 465 - 465.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the American Association for Clinical Chemistry.